FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017316449> ?p ?o ?g. }

• W2017316449 endingPage "187" @default.
• W2017316449 startingPage "183" @default.
• W2017316449 abstract "Antibodies against the epidermal growth factor receptor (EGFR), such as cetuximab, are effective in loco-regional advanced squamous cell carcinoma of the head and neck (SCCHN) in association with radiotherapy. Cutaneous reactions are well known as adverse events during treatment with EGFR inhibitors.To identify a multidisciplinary approach for mucous-cutaneous toxicity during cetuximab-radiotherapy treatment in order to reduce the risk of an early radio-chemotherapy interruption.The data of 38 patients with SCCHN receiving cetuximab and radiotherapy were retrospectively analyzed. The control group (n = 15) received the standardized treatments according to the severity of skin reactions with dermatologic visits only for high degrees of toxicity. The experimental group (n = 23) was monitored and daily treated by dermatologists since grade 1 of cutaneous toxicity. The primary end-point of our study was the mean days of antitumor therapy interruption.The mean number of days of antitumor therapy suspension was 12.6 (7.6) in the standard treatment group and 5.0 (6.6) in the experimental group (p = 0.002). This difference was observed for each grade of toxicity.The early interruption of radio-chemotherapy has a negative impact on survival in patients with SCCHN. In our study, a closer dermatological examination and treatment for all degrees of toxicity reduced early interruptions of chemo-radiotherapy." @default.
• W2017316449 created "2016-06-24" @default.
• W2017316449 creator A5008208200 @default.
• W2017316449 creator A5014425613 @default.
• W2017316449 creator A5021264703 @default.
• W2017316449 creator A5026203664 @default.
• W2017316449 creator A5048803221 @default.
• W2017316449 creator A5056852049 @default.
• W2017316449 creator A5070150511 @default.
• W2017316449 creator A5073296373 @default.
• W2017316449 creator A5083300221 @default.
• W2017316449 creator A5090832564 @default.
• W2017316449 date "2014-06-17" @default.
• W2017316449 modified "2023-10-18" @default.
• W2017316449 title "Adverse skin reactions during treatment with cetuximab plus radiotherapy: Multidisciplinary approach to minimize radio-chemotherapy interruption" @default.
• W2017316449 cites W1673015956 @default.
• W2017316449 cites W1896890211 @default.
• W2017316449 cites W1974024530 @default.
• W2017316449 cites W1990967992 @default.
• W2017316449 cites W1993233355 @default.
• W2017316449 cites W2004020565 @default.
• W2017316449 cites W2011513069 @default.
• W2017316449 cites W2017005150 @default.
• W2017316449 cites W2032766869 @default.
• W2017316449 cites W2039633811 @default.
• W2017316449 cites W2039979010 @default.
• W2017316449 cites W2046225622 @default.
• W2017316449 cites W2068937134 @default.
• W2017316449 cites W2070524877 @default.
• W2017316449 cites W2089663915 @default.
• W2017316449 cites W2099865988 @default.
• W2017316449 cites W2105927767 @default.
• W2017316449 cites W2112845420 @default.
• W2017316449 cites W2125016718 @default.
• W2017316449 cites W2126267208 @default.
• W2017316449 cites W2126948867 @default.
• W2017316449 cites W2138941169 @default.
• W2017316449 cites W2143574930 @default.
• W2017316449 cites W2145079916 @default.
• W2017316449 cites W2151730005 @default.
• W2017316449 cites W2155384808 @default.
• W2017316449 cites W2155933329 @default.
• W2017316449 cites W2156700619 @default.
• W2017316449 cites W2157036179 @default.
• W2017316449 cites W2167531081 @default.
• W2017316449 cites W2169083148 @default.
• W2017316449 cites W277071610 @default.
• W2017316449 doi "https://doi.org/10.3109/09546634.2014.927815" @default.
• W2017316449 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24852820" @default.
• W2017316449 hasPublicationYear "2014" @default.
• W2017316449 type Work @default.
• W2017316449 sameAs 2017316449 @default.
• W2017316449 citedByCount "4" @default.
• W2017316449 countsByYear W20173164492016 @default.
• W2017316449 countsByYear W20173164492017 @default.
• W2017316449 countsByYear W20173164492020 @default.
• W2017316449 countsByYear W20173164492021 @default.
• W2017316449 crossrefType "journal-article" @default.
• W2017316449 hasAuthorship W2017316449A5008208200 @default.
• W2017316449 hasAuthorship W2017316449A5014425613 @default.
• W2017316449 hasAuthorship W2017316449A5021264703 @default.
• W2017316449 hasAuthorship W2017316449A5026203664 @default.
• W2017316449 hasAuthorship W2017316449A5048803221 @default.
• W2017316449 hasAuthorship W2017316449A5056852049 @default.
• W2017316449 hasAuthorship W2017316449A5070150511 @default.
• W2017316449 hasAuthorship W2017316449A5073296373 @default.
• W2017316449 hasAuthorship W2017316449A5083300221 @default.
• W2017316449 hasAuthorship W2017316449A5090832564 @default.
• W2017316449 hasConcept C121608353 @default.
• W2017316449 hasConcept C126322002 @default.
• W2017316449 hasConcept C143998085 @default.
• W2017316449 hasConcept C16005928 @default.
• W2017316449 hasConcept C197934379 @default.
• W2017316449 hasConcept C2776694085 @default.
• W2017316449 hasConcept C2779438470 @default.
• W2017316449 hasConcept C2779998722 @default.
• W2017316449 hasConcept C2910486316 @default.
• W2017316449 hasConcept C29730261 @default.
• W2017316449 hasConcept C509974204 @default.
• W2017316449 hasConcept C526805850 @default.
• W2017316449 hasConcept C71924100 @default.
• W2017316449 hasConceptScore W2017316449C121608353 @default.
• W2017316449 hasConceptScore W2017316449C126322002 @default.
• W2017316449 hasConceptScore W2017316449C143998085 @default.
• W2017316449 hasConceptScore W2017316449C16005928 @default.
• W2017316449 hasConceptScore W2017316449C197934379 @default.
• W2017316449 hasConceptScore W2017316449C2776694085 @default.
• W2017316449 hasConceptScore W2017316449C2779438470 @default.
• W2017316449 hasConceptScore W2017316449C2779998722 @default.
• W2017316449 hasConceptScore W2017316449C2910486316 @default.
• W2017316449 hasConceptScore W2017316449C29730261 @default.
• W2017316449 hasConceptScore W2017316449C509974204 @default.
• W2017316449 hasConceptScore W2017316449C526805850 @default.
• W2017316449 hasConceptScore W2017316449C71924100 @default.
• W2017316449 hasIssue "2" @default.
• W2017316449 hasLocation W20173164491 @default.
• W2017316449 hasLocation W20173164492 @default.
• W2017316449 hasOpenAccess W2017316449 @default.

• next